Regencell Bioscience Holdings earnings were -$11.7M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest RGC earnings report on Jun 30, 2026 announced Q2 2026 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2026 ending Jun 30, 2026, RGC reported annual earnings of -$11.7M, with 226.5% growth.
Regencell Bioscience Holdings Earnings Reports & History FAQ
What were Regencell Bioscience Holdings's earnings last quarter?
Regencell Bioscience Holdings (NASDAQ: RGC) reported Q2 2026 earnings per share (EPS) of N/A, up N/A year over year. Total RGC earnings for the quarter were N/A. In the same quarter last year, Regencell Bioscience Holdings's earnings per share (EPS) was N/A.
Is Regencell Bioscience Holdings profitable or losing money?
As of the last Regencell Bioscience Holdings earnings report, Regencell Bioscience Holdings is currently losing money. Regencell Bioscience Holdings's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$11.70 million, a 226.49% increase year over year.
What was RGC's earnings growth in the past year?
As of Regencell Bioscience Holdings's earnings date in Q4 2026, Regencell Bioscience Holdings's earnings has grown year over year. RGC earnings in the past year totalled -$11.70 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.